HALO - Halozyme Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.35B
Enterprise Value 3
2.15B
Trailing P/E
N/A
Forward P/E 1
-37.33
PEG Ratio (5 yr expected) 1
-0.79
Price/Sales (ttm)
12.91
Price/Book (mrq)
8.98
Enterprise Value/Revenue 3
11.81
Enterprise Value/EBITDA 6
-62.93

Trading Information

Stock Price History

Beta (3Y Monthly) 1.60
52-Week Change 3-9.12%
S&P500 52-Week Change 36.81%
52 Week High 318.10
52 Week Low 313.24
50-Day Moving Average 315.96
200-Day Moving Average 316.25

Share Statistics

Avg Vol (3 month) 3755.21k
Avg Vol (10 day) 3716.86k
Shares Outstanding 5146.31M
Float 133.95M
% Held by Insiders 18.48%
% Held by Institutions 10.00%
Shares Short (Sep 30, 2019) 48.35M
Short Ratio (Sep 30, 2019) 410.74
Short % of Float (Sep 30, 2019) 46.44%
Short % of Shares Outstanding (Sep 30, 2019) 45.71%
Shares Short (prior month Aug 30, 2019) 47.93M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -23.53%
Operating Margin (ttm)-20.10%

Management Effectiveness

Return on Assets (ttm)-5.12%
Return on Equity (ttm)-16.62%

Income Statement

Revenue (ttm)181.88M
Revenue Per Share (ttm)1.26
Quarterly Revenue Growth (yoy)11.20%
Gross Profit (ttm)-8.53M
EBITDA -34.13M
Net Income Avi to Common (ttm)-42.8M
Diluted EPS (ttm)-0.30
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)287.46M
Total Cash Per Share (mrq)1.97
Total Debt (mrq)93.22M
Total Debt/Equity (mrq)35.85
Current Ratio (mrq)2.89
Book Value Per Share (mrq)1.79

Cash Flow Statement

Operating Cash Flow (ttm)-37.67M
Levered Free Cash Flow (ttm)-20.84M